Mizuho Forecasts Strong Price Appreciation for Tango Therapeutics (NASDAQ:TNGX) Stock

Key Points

• Mizuho raised its price target on Tango Therapeutics to $20 and kept an "outperform" rating, implying about a 22.29% upside; the consensus target is roughly $19.50 with a "Moderate Buy" average (9 Buys, 1 Hold, 1 Sell).
• The stock trades near $16.36 with a $2.33B market cap, a negative P/E, and reported last-quarter EPS of ($0.29) beating estimates by $0.02, while analysts forecast about ($1.19) EPS for the current fiscal year and a 12‑month range of $1.03–$17.63.
• Insiders sold ~133,884 shares (~$1.72M) over the last quarter (insiders still own 7.5%), while institutional investors increased stakes substantially — Adage, Goldman and Logos among the largest recent buyers — leaving institutions with ~79% ownership.

Tango Therapeutics (NASDAQ:TNGX - Get Free Report) had its target price increased by investment analysts at Mizuho from $19.00 to $20.00 in a report issued on Wednesday,Benzinga reports. The brokerage currently has an "outperform" rating on the stock. Mizuho's target price would suggest a potential upside of 22.29% from the stock's previous close.

Other research analysts have also recently issued reports about the company. Wolfe Research began coverage on Tango Therapeutics in a research report on Tuesday, November 18th. They set a "peer perform" rating for the company. Wall Street Zen lowered Tango Therapeutics from a "buy" rating to a "hold" rating in a research report on Saturday. Jefferies Financial Group reaffirmed a "buy" rating and set a $18.00 price target on shares of Tango Therapeutics in a research report on Thursday, March 5th. B. Riley Financial raised their price target on shares of Tango Therapeutics from $8.00 to $14.00 and gave the stock a "buy" rating in a research note on Tuesday, November 18th. Finally, Stifel Nicolaus lifted their price objective on shares of Tango Therapeutics from $15.00 to $24.00 and gave the company a "buy" rating in a report on Monday. Nine analysts have rated the stock with a Buy rating, one has issued a Hold rating and one has given a Sell rating to the stock. According to data from MarketBeat, the stock has an average rating of "Moderate Buy" and a consensus target price of $19.50.

Tango Therapeutics Stock Down 0.9%

Shares of NASDAQ:TNGX opened at $16.36 on Wednesday. The firm has a market cap of $2.33 billion, a price-to-earnings ratio of -18.92 and a beta of 1.76. Tango Therapeutics has a 12 month low of $1.03 and a 12 month high of $17.63. The company's fifty day simple moving average is $12.17 and its 200 day simple moving average is $9.61.

Tango Therapeutics (NASDAQ:TNGX - Get Free Report) last announced its earnings results on Thursday, March 5th. The company reported ($0.29) earnings per share for the quarter, topping analysts' consensus estimates of ($0.31) by $0.02. Tango Therapeutics had a negative net margin of 151.15% and a negative return on equity of 50.30%. Research analysts expect that Tango Therapeutics will post -1.19 earnings per share for the current fiscal year.

Insider Buying and Selling

In other Tango Therapeutics news, Director Barbara Weber sold 30,519 shares of the business's stock in a transaction that occurred on Tuesday, February 3rd. The stock was sold at an average price of $12.26, for a total transaction of $374,162.94. Following the transaction, the director owned 1,629,254 shares of the company's stock, valued at $19,974,654.04. The trade was a 1.84% decrease in their position. The transaction was disclosed in a document filed with the Securities & Exchange Commission, which is available through this link. Also, insider Adam Crystal sold 20,251 shares of the company's stock in a transaction that occurred on Thursday, March 5th. The stock was sold at an average price of $15.00, for a total value of $303,765.00. Following the sale, the insider owned 112,622 shares in the company, valued at approximately $1,689,330. This represents a 15.24% decrease in their position. The disclosure for this sale is available in the SEC filing. Over the last quarter, insiders have sold 133,884 shares of company stock worth $1,724,622. Corporate insiders own 7.50% of the company's stock.

Hedge Funds Weigh In On Tango Therapeutics

Hedge funds and other institutional investors have recently made changes to their positions in the company. Adage Capital Partners GP L.L.C. grew its stake in Tango Therapeutics by 322.5% in the 4th quarter. Adage Capital Partners GP L.L.C. now owns 10,607,924 shares of the company's stock valued at $93,986,000 after buying an additional 8,096,924 shares during the last quarter. Caligan Partners LP acquired a new stake in Tango Therapeutics during the fourth quarter worth approximately $33,047,000. Goldman Sachs Group Inc. boosted its holdings in shares of Tango Therapeutics by 227.4% during the fourth quarter. Goldman Sachs Group Inc. now owns 4,942,414 shares of the company's stock worth $43,790,000 after acquiring an additional 3,432,939 shares during the period. Logos Global Management LP grew its position in shares of Tango Therapeutics by 342.1% in the fourth quarter. Logos Global Management LP now owns 4,200,000 shares of the company's stock valued at $37,212,000 after purchasing an additional 3,250,000 shares during the last quarter. Finally, Paradigm Biocapital Advisors LP acquired a new position in shares of Tango Therapeutics in the third quarter valued at approximately $25,924,000. 78.99% of the stock is owned by institutional investors.

About Tango Therapeutics

Tango Therapeutics is a clinical-stage biotechnology company dedicated to developing precision medicines that exploit genetic vulnerabilities in cancer cells. Leveraging a proprietary synthetic lethality platform, the company identifies and targets tumor-specific dependencies in DNA damage response and related pathways. By focusing on tumor cell collateral sensitivities, Tango aims to bring differentiated small-molecule therapies to patients with genetic alterations that confer increased susceptibility to targeted inhibition.

The company's lead pipeline comprises several early-stage programs, including inhibitors designed to selectively disable DNA repair proteins in tumor cells while sparing normal tissues.

This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest reporting and unbiased coverage. Please send any questions or comments about this story to contact@marketbeat.com.